Resistance to β-lactam antibiotics can be mediated by metallo-β-lactamase enzymes
(MBLs). An MBL inhibitor could restore the effectiveness of β-lactams. We report on the …

The rise of antibiotic resistance calls for new therapeutics targeting resistance factors such
as the New Delhi metallo-β-lactamase 1 (NDM-1), a bacterial enzyme that degrades β …

We report the discovery of a promising NDM-1 inhibitor, ebselen, through a cell-based
screening approach. Enzymatic kinetic study and ESI-MS analysis suggested that ebselen …

Abstract Bacteria carrying New Delhi metallo-β-lactamase-1 (New Delhi metallo-β-
lactamase, NDM-1) resistance gene is a new type of “superbug”, which can hydrolyze …

Pathogenic Gram-negative bacteria resistant to almost all β-lactam antibiotics are a major
public health threat. Zn (II)-dependent or metallo-β-lactamases (MBLs) produced by these …

New Delhi metallo-β-lactmase-1 (NDM-1) has recently emerged as a global threat because
of its ability to confer resistance to almost all clinically used β-lactam antibiotics, its presence …

New Delhi metallo-beta-lactamase (NDM-1) is a novel metallo-beta-lactamase (MBL).
Sporadic cases of NDM-1 positive strains have been reported from different countries …

New antibiotics are needed to battle growing antibiotic resistance, but the development
process from hit, to lead, and ultimately to a useful drug takes decades. Although progress in …

The New Delhi Metallo-β-lactamase (NDM-1) gene makes multiple pathogenic
microorganisms resistant to all known β-lactam antibiotics. The rapid emergence of NDM-1 …

Metallo-β-lactamases (MBLs) are a growing threat to the use of almost all clinically used β-
lactam antibiotics. The identification of broad-spectrum MBL inhibitors is hampered by the …